[{"id":"beb344ab-95cf-420e-8ccd-b61bc4f7a537","acronym":"","url":"https://clinicaltrials.gov/study/NCT07097363","created_at":"2025-08-02T14:05:17.045Z","updated_at":"2025-08-02T14:05:17.045Z","phase":"Phase 2","brief_title":"Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT07097363","lead_sponsor":"University of Washington","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/01/2026","start_date":" 01/01/2026","primary_txt":" Primary completion: 05/31/2030","primary_completion_date":" 05/31/2030","study_txt":" Completion: 05/31/2030","study_completion_date":" 05/31/2030","last_update_posted":"2025-07-31"},{"id":"a4247f5e-b84a-4f2b-a095-1fca8e76f331","acronym":"","url":"https://clinicaltrials.gov/study/NCT06905509","created_at":"2025-08-02T14:06:01.421Z","updated_at":"2025-08-02T14:06:01.421Z","phase":"Phase 2","brief_title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","source_id_and_acronym":"NCT06905509","lead_sponsor":"University of California, Davis","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 08/01/2030","study_completion_date":" 08/01/2030","last_update_posted":"2025-04-01"},{"id":"8e3b627a-4aef-4d49-a1cb-f09137cdb6c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06536049","created_at":"2025-02-25T15:21:55.068Z","updated_at":"2025-02-25T15:21:55.068Z","phase":"Phase 1/2","brief_title":"Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT06536049","lead_sponsor":"Yazeed Sawalha","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Epkinly (epcoritamab-bysp)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-12"},{"id":"26aecd28-3309-47c0-96ca-e8aaf2f02780","acronym":"EPCORE DLBCL-1","url":"https://clinicaltrials.gov/study/NCT04628494","created_at":"2021-03-26T11:44:28.238Z","updated_at":"2025-02-25T16:53:23.428Z","phase":"Phase 3","brief_title":"A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL","source_id_and_acronym":"NCT04628494 - EPCORE DLBCL-1","lead_sponsor":"Genmab","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" CD20 positive","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epkinly (epcoritamab-bysp)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 552","initiation":"Initiation: 01/13/2021","start_date":" 01/13/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-02-04"},{"id":"37db9b88-cfea-407b-b290-ec67bb7844d2","acronym":"EPCORE NHL-5","url":"https://clinicaltrials.gov/study/NCT05283720","created_at":"2022-03-17T12:53:27.504Z","updated_at":"2025-02-25T16:54:10.677Z","phase":"Phase 2","brief_title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05283720 - EPCORE NHL-5","lead_sponsor":"Genmab","biomarkers":" BCL2 • CD20 • CCND1 • BCL6","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2 • CD20 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)"],"overall_status":"Recruiting","enrollment":" Enrollment 622","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 11/01/2032","primary_completion_date":" 11/01/2032","study_txt":" Completion: 11/01/2032","study_completion_date":" 11/01/2032","last_update_posted":"2025-02-04"},{"id":"4bcfc2a3-0cc8-4da8-bbde-44b5b717afd2","acronym":"EPCORE Peds-1","url":"https://clinicaltrials.gov/study/NCT05206357","created_at":"2022-01-25T15:53:41.303Z","updated_at":"2025-02-25T16:54:07.085Z","phase":"Phase 1","brief_title":"Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab","source_id_and_acronym":"NCT05206357 - EPCORE Peds-1","lead_sponsor":"Genmab","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 10/04/2022","start_date":" 10/04/2022","primary_txt":" Primary completion: 11/01/2028","primary_completion_date":" 11/01/2028","study_txt":" Completion: 11/01/2028","study_completion_date":" 11/01/2028","last_update_posted":"2025-02-04"},{"id":"5d7df1e1-4350-4f4d-84d5-eafdf2cf1c33","acronym":"EPCORE DLBCL-3","url":"https://clinicaltrials.gov/study/NCT05660967","created_at":"2022-12-21T14:58:58.070Z","updated_at":"2025-02-25T16:54:37.811Z","phase":"Phase 2","brief_title":"Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT05660967 - EPCORE DLBCL-3","lead_sponsor":"Genmab","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 03/06/2023","start_date":" 03/06/2023","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2025-02-04"},{"id":"183d1ef7-c946-4ec1-95d1-e0802e6a3e7c","acronym":"EPCORE NHL-6","url":"https://clinicaltrials.gov/study/NCT05451810","created_at":"2022-07-11T11:54:54.294Z","updated_at":"2024-07-02T16:34:58.948Z","phase":"Phase 2","brief_title":"A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma","source_id_and_acronym":"NCT05451810 - EPCORE NHL-6","lead_sponsor":"Genmab","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 translocation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 08/17/2022","start_date":" 08/17/2022","primary_txt":" Primary completion: 08/29/2027","primary_completion_date":" 08/29/2027","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2024-06-04"},{"id":"19564d20-8ce4-4508-8710-2dc03972dfff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05201248","created_at":"2022-01-21T14:58:14.779Z","updated_at":"2024-07-02T16:34:59.188Z","phase":"Phase 1","brief_title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05201248","lead_sponsor":"Genmab","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 translocation","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • Epkinly (epcoritamab-bysp)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 12/13/2024","primary_completion_date":" 12/13/2024","study_txt":" Completion: 12/13/2024","study_completion_date":" 12/13/2024","last_update_posted":"2024-06-04"},{"id":"bb247996-61a2-4f60-a6a4-3c70792474cc","acronym":"EPCORE CLL-1","url":"https://clinicaltrials.gov/study/NCT04623541","created_at":"2021-01-19T20:34:51.454Z","updated_at":"2024-07-02T16:34:58.929Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","source_id_and_acronym":"NCT04623541 - EPCORE CLL-1","lead_sponsor":"Genmab","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 11/25/2020","start_date":" 11/25/2020","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2024-06-04"},{"id":"89d85ce4-ea03-4058-ba7a-82fb284611ca","acronym":"EPCORE NHL-2","url":"https://clinicaltrials.gov/study/NCT04663347","created_at":"2021-06-15T19:53:31.777Z","updated_at":"2024-07-02T16:34:59.645Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","source_id_and_acronym":"NCT04663347 - EPCORE NHL-2","lead_sponsor":"Genmab","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • lenalidomide • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • vincristine • bendamustine • Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 662","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 03/31/2029","primary_completion_date":" 03/31/2029","study_txt":" Completion: 03/31/2029","study_completion_date":" 03/31/2029","last_update_posted":"2024-05-31"},{"id":"4095393f-1afe-4397-9aa9-0d3e7de48147","acronym":"","url":"https://clinicaltrials.gov/study/NCT06045247","created_at":"2023-09-21T15:10:50.286Z","updated_at":"2024-07-02T16:35:00.377Z","phase":"Phase 2","brief_title":"Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT06045247","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":" | ","alterations":" MYC rearrangement • BCL2 rearrangement","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • vincristine • Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/05/2024","start_date":" 01/05/2024","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 07/31/2030","study_completion_date":" 07/31/2030","last_update_posted":"2024-05-29"},{"id":"b1d8902f-dbcd-4102-80b2-054da7832a9b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05783609","created_at":"2023-03-24T16:04:17.931Z","updated_at":"2024-07-02T16:35:02.222Z","phase":"Phase 2","brief_title":"Epcoritamab and Rituximab for First-line Follicular Lymphoma","source_id_and_acronym":"NCT05783609","lead_sponsor":"Reid Merryman, MD","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 06/21/2023","start_date":" 06/21/2023","primary_txt":" Primary completion: 01/22/2026","primary_completion_date":" 01/22/2026","study_txt":" Completion: 02/22/2029","study_completion_date":" 02/22/2029","last_update_posted":"2024-05-21"},{"id":"c7ba19cf-fcd0-4cee-a3ee-650a1852ae3a","acronym":"EPCORE DLBCL-2","url":"https://clinicaltrials.gov/study/NCT05578976","created_at":"2022-10-13T17:58:22.431Z","updated_at":"2024-07-02T16:35:05.573Z","phase":"Phase 3","brief_title":"A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)","source_id_and_acronym":"NCT05578976 - EPCORE DLBCL-2","lead_sponsor":"Genmab","biomarkers":" ALK • BCL2 • CD20 • BCL6","pipe":" | ","alterations":" ALK positive","tags":["ALK • BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 900","initiation":"Initiation: 02/08/2023","start_date":" 02/08/2023","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 12/30/2029","study_completion_date":" 12/30/2029","last_update_posted":"2024-05-07"},{"id":"011a0202-f758-49ee-967a-ff9bf14eff69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05852717","created_at":"2023-05-10T21:04:00.721Z","updated_at":"2024-07-02T16:35:12.247Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma","source_id_and_acronym":"NCT05852717","lead_sponsor":"Dipenkumar Modi","biomarkers":" ALK • MYC • BCL2 • CD20 • BCL6 • CD4","pipe":" | ","alterations":" ALK positive • BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • MYC • BCL2 • CD20 • BCL6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-03-29"},{"id":"212fcd2e-5a80-4c72-89a4-232239fbeb01","acronym":"","url":"https://clinicaltrials.gov/study/NCT06287398","created_at":"2024-03-01T20:32:57.876Z","updated_at":"2024-07-02T16:35:16.889Z","phase":"Phase 2","brief_title":"Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT \u0026 Epcor Consolidation in Patients With Relapsed LBCL","source_id_and_acronym":"NCT06287398","lead_sponsor":"Australasian Leukaemia and Lymphoma Group","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • oxaliplatin • Epkinly (epcoritamab-bysp)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2031","study_completion_date":" 11/01/2031","last_update_posted":"2024-03-01"},{"id":"a431e6a9-3e1c-496d-931c-96bd3ccb3085","acronym":"REFRACT","url":"https://clinicaltrials.gov/study/NCT05848765","created_at":"2023-05-08T15:04:03.419Z","updated_at":"2024-07-02T16:35:27.830Z","phase":"Phase 2","brief_title":"Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy","source_id_and_acronym":"NCT05848765 - REFRACT","lead_sponsor":"University of Birmingham","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • bendamustine • Epkinly (epcoritamab-bysp)"],"overall_status":"Recruiting","enrollment":" Enrollment 284","initiation":"Initiation: 09/04/2023","start_date":" 09/04/2023","primary_txt":" Primary completion: 05/31/2029","primary_completion_date":" 05/31/2029","study_txt":" Completion: 11/30/2031","study_completion_date":" 11/30/2031","last_update_posted":"2023-11-29"}]